About this item:

19 Views | 16 Downloads

Author Notes:

Correspondence: Ursula A. Kelly, PhD, Joseph Maxwell Cleland Atlanta VA Medical Center and Nell Hodgson Woodruff School of Nursing, 1670 Clairmont Rd, Decatur, GA 30033 (ukelly@emory.edu; ursula.kelly@va.gov).

Author Contributions: Drs Kelly and Higgins had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Zaccari, Haywood, Patel, Emerson, Kelly. Acquisition, analysis, or interpretation of data: Zaccari, Higgins, Hubbard, Loftis, Kelly. Drafting of the manuscript: All authors. Critical review of the manuscript for important intellectual content: Zaccari, Higgins, Emerson, Hubbard, Loftis, Kelly. Statistical analysis: Higgins. Obtained funding: Kelly. Administrative, technical, or material support: Zaccari, Haywood, Emerson, Hubbard, Loftis. Supervision: Zaccari, Patel, Emerson, Loftis, Kelly.

Competing interests: Mr Emerson reported receiving grants from the Justice Resource Institute and a small amount of funding from the US Department of Veterans Affairs (VA) to cover a portion of his time during the conduct of the study. Dr Loftis reported receiving grants from the Department of Veterans Affairs Biomedical Laboratory Research and Development and National Institutes of Health during the conduct of the study and holding a patent for recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction (No. US 8 685 404 B2) licensed to Virogenomics BioDevelopment, Inc. No other disclosures were reported.

Subjects:

Research Funding:

This study was funded by award I01 HX001087-02 from the VA Office of Research & Development, Health Services Research & Development (Dr Kelly). Additional support was received from the Learning Health Systems grant K12 HS026370 from the Agency for Healthcare Research and Quality (Dr Zaccari); Merit Review Award 5 I01 BX002061-06 from the VA Biomedical Laboratory Research and Development (Dr Loftis); and VA Health Services Research & Development Los Angeles Center of Innovation (project ID: CIN 13-417) for manuscript preparation.

Keywords:

  • posttraumatic stress disorder
  • US Department of Veterans Affairs
  • Trauma Center Trauma-Sensitive Yoga
  • military sexual trauma

Yoga vs Cognitive Processing Therapy for Military Sexual Trauma–Related Posttraumatic Stress Disorder

Tools:

Journal Title:

JAMA Network Open

Volume:

Volume 6, Number 12

Publisher:

, Pages e2344862-None

Type of Work:

Article | Final Publisher PDF

Abstract:

Importance First-line treatment for posttraumatic stress disorder (PTSD) in the US Department of Veterans Affairs (VA), ie, trauma-focused therapy, while effective, is limited by low treatment initiation, high dropout, and high treatment refraction. Objective To evaluate the effectiveness of Trauma Center Trauma-Sensitive Yoga (TCTSY) vs first-line cognitive processing therapy (CPT) in women veterans with PTSD related to military sexual trauma (MST) and the hypothesis that PTSD outcomes would differ between the interventions. Design, Setting, and Participants This multisite randomized clinical trial was conducted from December 1, 2015, to April 30, 2022, within 2 VA health care systems located in the southeast and northwest. Women veterans aged 22 to 71 years with MST-related PTSD were enrolled and randomized to TCTSY or CPT. Interventions The TCTSY intervention (Hatha-style yoga focusing on interoception and empowerment) consisted of 10 weekly, 60-minute group sessions, and the CPT intervention (cognitive-based therapy targeting modification of negative posttraumatic thoughts) consisted of 12 weekly, 90-minute group sessions. Main Outcome and Measures Sociodemographic data were collected via self-report survey. The primary outcome, PTSD symptom severity, was assessed using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) and PTSD Checklist for DSM-5 (PCL-5). Assessments were conducted at baseline, midintervention, 2 weeks post intervention, and 3 months post intervention. Results Of 200 women veterans who consented to participate, the intent-to-treat sample comprised 131 participants (mean [SD] age, 48.2 [11.2] years), with 72 randomized to TCTSY and 59 randomized to CPT. Treatment was completed by 47 participants (65.3%) in the TCTSY group and 27 (45.8%) in the CPT group, a 42.6% higher treatment completion rate in the TCTSY group (P = .03). Both treatment groups improved over time on the CAPS-5 (mean [SD] scores at baseline: 36.73 [8.79] for TCTSY and 35.52 [7.49] for CPT; mean [SD] scores at 3 months: 24.03 [11.55] for TCTSY and 22.15 [13.56]) and the PCL-5 (mean [SD] scores at baseline: 49.62 [12.19] for TCTSY and 48.69 [13.62] for CPT; mean [SD] scores at 3 months: 36.97 [17.74] for TCTSY and 31.76 [12.47]) (P < .001 for time effects). None of the group effects or group-by-time effects were significant. Equivalence analyses of change scores were not significantly different between the TCTSY and CPT groups, and the two one-sided test intervals fell within the equivalence bounds of plus or minus 10 for CAPS-5 for all follow-up time points. Conclusions and Relevance In this comparative effectiveness randomized clinical trial, TCTSY was equivalent to CPT in reducing PTSD symptom severity, with both groups improving significantly. The higher treatment completion rate for TCTSY indicates its higher acceptability as an effective and acceptable PTSD treatment for women veterans with PTSD related to MST that could address current VA PTSD treatment limitations.

Copyright information:

2023 Zaccari B et al. JAMA Network Open.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote